NEUARTIGE KALIUMKANALINHIBITOREN

European patent · EP3419973 · In force

Register entry

Publication number
EP3419973
Application number
EP17708164
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Feb 23, 2017
Published
Jan 2, 2019
Granted
Apr 8, 2020
Protection ends at the latest
Feb 22, 2037
Next annual fee due
Feb 28, 2027
IPC classes
C07D 403/12 (2006.01)
C07D 401/12 (2006.01)
C07D 235/30 (2006.01)
C07D 405/12 (2006.01)
C07D 413/12 (2006.01)
C07D 417/12 (2006.01)
A61K 31/4188 (2006.01)
A61P 9/00 (2006.01)
Priority
EP 16020053 24.02.2016
PCT application
PCT/EP2017/025033 23.02.2017
PCT publication
WO2017/144183 31.08.2017
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Mar 1, 2026

    Change

    Published in Swissreg on 01.03.2026

  2. Mar 6, 2025

    Change

    Published in Swissreg on 06.03.2025

  3. Mar 1, 2024

    Change

    Published in Swissreg on 01.03.2024

  4. Mar 6, 2023

    Change

    Published in Swissreg on 06.03.2023

  5. Apr 15, 2020

    Agent entered

    Representative
    TR-IP Consulting LLC, Route du Coutset 18, 1485 Nuvilly

    Published in Swissreg on 15.04.2020

  6. Apr 8, 2020

    Granted

    Published in Swissreg on 08.04.2020

Parties

Holder

Acesion Pharma ApS

Ole Maaløes Vej 3, 2200 Copenhagen N, DK

Agent

TR-IP Consulting Sàrl

TR-IP Consulting LLC

Route du Coutset 18, 1485 Nuvilly

In liquidation

Inventor

METE, Antonio

Loughborough Leicestershire LE11 3LB, GB

SØRENSEN, Ulrik Svane

3500 Værløse, DK

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.